Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Breeze Meds vs NextMeds

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Breeze Meds logo

Breeze Meds

7.7
★★★3.9/5

Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy

Visit Breeze Meds
VS
NextMeds logo

NextMeds

9.2
★★★★4.6/5

Best for: semaglutide at $79/month, 59% under the register median

Visit NextMeds

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, NextMeds opens cheaper — $79/mo against $199, and NextMeds finishes ahead, 9.2 to 7.7. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

Breeze Meds

Injection (weekly)Compounded
$199/mo
semaglutide

Displayed on rendered homepage card 'GLP-1 Injection / Starting at $199'. Checkout catalog JS shows monthly:199 with oldPrice:249 and bundles threeMonthly:748 / sixMonthly:1248 / yearly:2298 ($191.50/mo effective).

Injection (weekly)Compounded
$399$299/mo
Save 25% right now
tirzepatide

Homepage card displays 'Starting at $399'. The site's own checkout catalog (/_nuxt/tdPmVDYT.js) prices it monthly:299 with oldPrice:399 (bundles 1068/3mo, 1918/6mo, 3498/yr) — but checkout is intake-gated, so $299 was found in code, not rendered publicly; keep $399 as the published price and treat $299 as an unconfirmed in-checkout promo.

Oral dissolvable tablet (daily)Compounded · oral
$299/mo
semaglutide

Rendered card 'Oral Semaglutide / Starting at $299 / One dissolvable tablet per day.' Catalog bundles: 899/3mo, 1799/6mo, 3498/yr.

Oral dissolvable tablet (daily)Compounded · oral
$399/mo
tirzepatide

Rendered card 'Oral Tirzepatide / Starting at $399 / One dissolvable tablet per day.' Catalog bundles: 1199/3mo, 2399/6mo, 4799/yr.

NextMeds

InjectableCompounded
$79/mo
semaglutide

Compounded Semaglutide Membership, drug included when prescribed, alongside telehealth visits, a care coach, a dietitian and shipping. $79 is the month-to-month rate read from the pricing section on 2026-08-14. The site headline reads 'from $49/mo': that is the 12-month prepaid term divided down, not a monthly price, and the ladder between them is 3-month $76, 6-month $73, 12-month $49. A summer promotion was running with a stated end of August 20, so $79 may itself be discounted.

InjectableCompounded
$109/mo
tirzepatide

Compounded Tirzepatide Membership, drug included when prescribed, alongside telehealth visits, a care coach, a dietitian and shipping. $109 is the month-to-month rate read from the pricing section on 2026-08-14. The advertised 'GLP-1 + GIP: $95' is the 12-month prepaid term divided down; the ladder is 3-month $105, 6-month $100, 12-month $95. A summer promotion was running with a stated end of August 20, so $109 may itself be discounted.

What’s included

Breeze Meds

Covered by the monthly price

Medication

In the price

Clinician visits

Not stated

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

NextMeds

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

In the price

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

Breeze Meds

7.7/10

Overall

NextMeds

9.2/10

Value25%

4.6A
vs
B
10.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

9.0A
vs
B
7.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

4.5A
vs
B
8.5

Features & Coverage

FeatureBreeze MedsNextMeds
Starting Price$199/mo$79/mo
Features6 features8 features
States Available5050
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted✓ Yes
FDA WarningsNoneNone

About Breeze Meds

Breeze Meds is a Georgia-based telehealth seller shipping to all 50 states, with compounded semaglutide at $199/mo, tirzepatide at $399/mo, and NAD+ at $169/mo. It is LegitScript certified, names its medical team (Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD), and works through a 4-pharmacy compounding network via Lion MD: Belmar, Strive, Epiq Scripts, and Casa Pharma Rx.

Read our full Breeze Meds review →

About NextMeds

Membership is a single flat monthly charge, and inside it sit free shipping, a registered dietitian holding a license, a care coach working 1:1, telehealth visits and the drug itself where one is prescribed. Insurance is not billed. A free assessment online goes to a licensed provider, who adds a phone or video consult in states that demand one, then prescribes if it fits. Compounding pharmacies within the Next Meds network, all licensed, ship. Auto-renewal does not exist, cancellation is open, and all 50 states can order compounded tirzepatide and semaglutide.

Read our full NextMeds review →

Pros & Cons

Breeze Meds

What we like

  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly figure covers medication and shipping
  • Coverage is published for all 50 states
  • Names 4 dispensing pharmacies, which most sellers in this register do not do
  • No FDA warning letter matched this operator when we searched our enforcement register
  • Both oral and injectable options are on record, so the format is a choice rather than a condition

Watch-outs

  • Tirzepatide at $399 a month, 49% above the $267 register median for the same drug and form
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

NextMeds

What we like

  • Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
  • Tirzepatide at $109 a month, 59% below the $267 median for the same drug and form across this register
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
  • The monthly figure covers medication, consult, shipping, coaching
  • Coverage is published for all 50 states
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: NextMeds

NextMeds takes it, 9.2 against 7.7, and it is especially strong on semaglutide at $79/month, 59% under the register median. Breeze Meds is no weak second and may fit you better on knowing which pharmacy fills the vial — it names Belmar Pharmacy.

Choose Breeze Meds if…

You want knowing which pharmacy fills the vial — it names Belmar Pharmacy and an opening price near $199 a month.

Choose NextMeds if…

You want semaglutide at $79/month, 59% under the register median and an opening price near $79 a month.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.3

Telos Rx

Starting below a standard dose, with microdose tiers

7.0

MyDrHank

An oral route if you will not self-inject

6.0

SkinnyRx

Starting below a standard dose, with microdose tiers

Breeze Meds vs NextMeds: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring Breeze Meds and NextMeds head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.